Just a week after it secured FDA approval, Eli Lilly’s Zepbound now faces a challenge from Novo Nordisk’s investigational next-generation weight-loss candidate CagriSema in a Phase III trial.
Tag Archive for: CagriSema
Novo Nordisk shared that its clinical trial of CagriSema, a combination injection for overweight people with type II diabetes, resulted in a 15.6% body weight reduction compared to the drugs dosed individually.
